Ocular Therapeutix™ to Participate in Two Investor Conferences in April
Rhea-AI Summary
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on retina treatments, has announced its participation in two major investor conferences this April. The first event is the 24th Annual Needham Virtual Healthcare Conference, where Dr. Pravin U. Dugel, Executive Chairman, President and CEO, will present on Monday, April 7, 2025, at 3:00 PM ET in a virtual format.
The second event is the Piper Sandler Spring Biopharma Symposium in Boston, MA, scheduled for Thursday, April 17, 2025, where the company will host one-on-one meetings with investors. Interested parties can access a live webcast of the Needham presentation through the Events and Presentations section of Ocular's Investor Relations webpage.
Positive
- None.
Negative
- None.
News Market Reaction – OCUL
On the day this news was published, OCUL declined 3.30%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April:
24th Annual Needham Virtual Healthcare Conference
Presentation Date: Monday, April 7, 2025
Presentation Time: 3:00 PM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Virtual
Piper Sandler Spring Biopharma Symposium
Date: Thursday, April 17, 2025
Ocular Therapeutix to host investor one-on-one meetings
Location: Boston, MA
A live webcast of the Needham presentation can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral hydrogel or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
When is Ocular Therapeutix (OCUL) presenting at the Needham Healthcare Conference 2025?
Where can investors watch OCUL's Needham Conference presentation?
What investor events is OCUL attending in April 2025?
Who will represent OCUL at the Needham Healthcare Conference 2025?
